12 Health Care Stocks Moving In Thursday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Thursday's pre-market session, several healthcare stocks showed significant movement. Bio-Path Holdings, SINTX Techs, 23andMe Holding, Benitec Biopharma, Trevena, and Citius Pharma were among the gainers with notable percentage increases in their stock prices. Conversely, NRX Pharmaceuticals, Soligenix, Sonoma Pharmaceuticals, Mustang Bio, Dynatronics, and SeaStar Medical Holding were the losers, experiencing declines in their stock prices. SeaStar Medical specifically mentioned its Q4 earnings release two days ago.
April 18, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Path Holdings saw a significant pre-market increase of 43.8% to $4.66, with a market value of $3.5 million.
The substantial pre-market increase in Bio-Path Holdings' stock price suggests positive investor sentiment, likely leading to short-term upward price momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
23andMe Holding's stock increased by 26.61% to $0.45, with a market cap of $217.7 million.
The notable pre-market increase for 23andMe Holding suggests positive market reception, likely contributing to short-term stock appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
SINTX Techs' shares rose by 39.41% to $0.05, with a market cap of $6.3 million.
The significant pre-market rise in SINTX Techs' shares indicates strong investor interest, potentially leading to further short-term gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
SeaStar Medical Holding's shares fell by 9.46% to $0.63, with a market cap of $47.7 million, following its Q4 earnings release.
The decline in SeaStar Medical Holding's stock price post-Q4 earnings suggests the market's reaction was negative, likely affecting short-term stock performance.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 95
NEGATIVE IMPACT
NRX Pharmaceuticals experienced a pre-market decline of 22.5% to $3.24, with a market cap of $31.0 million.
The significant pre-market decline in NRX Pharmaceuticals' stock price indicates negative investor sentiment, likely leading to short-term downward price pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90